ONC BeiGene Ltd.

Price (delayed)

$325.9

Market cap

$36.27B

P/E Ratio

905.28

Dividend/share

N/A

EPS

$0.36

Enterprise value

$33.53B

?
Relative Growth: Rel. Growth: 84
Relative Strength: Rel. Strength: 52
Relative Valuation: Rel. Valuation: 15
Relative Profitability: Rel. Profitability: 95

BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People's Republic of China, the United States, and internationally. Its products include BRUKINSA to treat relapsed/refractory (R/R) ...

Highlights
BeiGene's quick ratio has surged by 94% YoY and by 7% QoQ
The company's EPS has surged by 80% QoQ
BeiGene's debt has soared by 106% YoY and by 2.7% from the previous quarter

Key stats

What are the main financial stats of ONC

ONC stock price

How has the BeiGene stock price performed over time
Intraday
-0.27%
1 week
4.45%
1 month
17.6%
1 year
9.93%
YTD
7.27%
QTD
14.36%

Financial performance

How have BeiGene's revenue and profit performed over time
Revenue
$5.74B
Gross profit
$5.07B
Operating income
$685.94M
Net income
$513.02M
Gross margin
88.3%
Net margin
8.9%
BeiGene's net margin has soared by 195% YoY and by 65% from the previous quarter
The net income has surged by 79% since the previous quarter
BeiGene's operating income has surged by 53% QoQ
ONC's operating margin is up by 43% since the previous quarter

Price vs fundamentals

How does ONC's price correlate with its fundamentals

Growth

What is BeiGene's growth rate over time

Valuation

What is BeiGene stock price valuation
P/E
905.28
P/B
7.6
P/S
6.31
EV/EBIT
44.58
EV/EBITDA
37.17
EV/Sales
5.84
The company's EPS has surged by 80% QoQ
The equity has grown by 36% YoY and by 9% from the previous quarter
The price to book (P/B) is 31% higher than the 5-year quarterly average of 5.8
ONC's price to sales (P/S) is 44% lower than its 5-year quarterly average of 11.3
The revenue has grown by 37% YoY and by 7% from the previous quarter

Efficiency

How efficient is BeiGene business performance
The company's return on assets has surged by 200% YoY and by 63% QoQ
ONC's return on equity has surged by 66% since the previous quarter
The company's return on sales rose by 47% QoQ
BeiGene's ROIC has increased by 38% from the previous quarter

Dividends

What is ONC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ONC.

Financial health

How did BeiGene financials performed over time
The total assets is 126% greater than the total liabilities
BeiGene's quick ratio has surged by 94% YoY and by 7% QoQ
The current ratio has soared by 86% year-on-year and by 7% since the previous quarter
BeiGene's debt is 57% less than its equity
BeiGene's debt has soared by 106% YoY and by 2.7% from the previous quarter
BeiGene's debt to equity has surged by 54% YoY but it has decreased by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.